The Billion Dollar Ice Cream Flavor. How One $DRTS Deal Changes Everything.

$100 a share is a CONSERVATIVE estimate when $DRTS completes its roadmap

Alpha Tau Medical ($DRTS ) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical data and partnership momentum via Tolmar's prostate cancer tie-up. A breakthrough year for this oncology innovator. New report: seekingalpha.com/article/491…

“Alpha Tau (NASDAQ: $DRTS is an exciting company with a lot of shots on goal” Read the full @SeekingAlpha article here: seekingalpha.com/article/491…

FDA approval means more people are going to survive recurring, inoperable brain cancer (rGBM) because of $DRTS

JUST IN: The FDA Approves the $DRTS GBM Trial Completion, with the 3 months follow up showing no signs of the cancer! “This is a truly phenomenal outcome, no adverse events, no toxicity, and remained with complete response”

Alpha Tau (NASDAQ: $DRTS) Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control and Two Complete Responses alphatau.com/single-post/alp…

Alpha Tau (NASDAQ: $DRTS) will host a Webinar on June 17, 2026 at 10:00 AM IST (03:00 AM ET) in Jerusalem During the meeting, Alpha Tau CEO Uzi Sofer and CFO Raphi Levy will present (in Hebrew) a comprehensive overview of the company's operations, business strategy, and progress on clinical, regulatory, and commercial milestones expected in the coming year, in the clinical development program of Alpha DaRT® technology in several oncology indications. In addition, the new strategic collaboration with Tolmar in the United States will be discussed, followed by time for questions and answers. Sign up here: publicators.com/app/drd.asp?…

Most people have no idea how practically deployable $DRTS Alpha DaRT actually is. Just read the clinical best practices paper (PMC12036777) and I can't find negative observations when I actively seek them out. pmc.ncbi.nlm.nih.gov/article… 1

This clarifies how Alpha Tau Medical ( $DRTS ) will leverage one outstanding commercial deal to become a critical part of the standard of care for prostate cancer and then SoC for recurring GBM and PDAC Pancreatic cancer. Well done! When you see the terms in this light, you realize Alpha Tau medical is going to sell a lot of ice cream around the world.

Targeted alpha therapy is the next big thing in oncology: single-cell killing power, works on hypoxic tumors, and can generate systemic immune responses when combined with checkpoint inhibitors. Save this $DRTS

1 year later...up 207% -> 280% ATH $DRTS

Barclays raises $DRTS Price Target to 17$ after the commercialization deal announced yesterday Other analysts are expected to upgrade as well, following the commercialization deal with Tolmar and all the additional great news Alpha Tau has shared recently

Alpha Tau (NASDAQ: $DRTS) CEO says there are potentially 60-80K patients a year for Recurring Prostate Cancer With a 60% net-sales supply price, that’s potentially Billions in annual revenue for the company from this deal

$DRTS trial data release schedule I'm watching: Summer 2026: Final results from Alpha Tau's combination study of Alpha DaRT pembrolizumab (KEYTRUDA) in head and neck cancer are expected to be presented. Aug 11th 2026: expected earnings release will likely include updates across all active programs. Late 2026 / Early 2027: ReSTART Trial (skin cancer/SCC): The U.S. pivotal trial for recurrent cutaneous squamous cell carcinoma (SCC) has completed patient treatment; full data is expected by year-end for an FDA PMA submission, aided by the company's FDA Breakthrough Device Designation and rolling application already in place. IMPACT Trial (pancreatic cancer): The trial has been expanded to 40 patients, with recruitment expected to finish next quarter (Q3 2026) and data expected by year-end. REGAIN Trial (glioblastoma): After reporting the strong May 2026 interim results (67% complete response, 100% local disease control in 3 patients), the company is awaiting FDA clearance to treat additional patients; more data should follow as enrollment expands.

This is the thunder and lightning. $DRTS is using physics to target the tumor and $RVMD is using chemistry. Together, they will likely be stronger than alone.

$RVMD and $DRTS featured together on Fox Business during ASCO Both companies presented promising Survival Data for Pancreatic Cancer Could we see a combined trial coming for future use together?

17.1 months median overall survival in heavily pretreated locally advanced pancreatic cancer. filed today via 6-K, also presented at ASCO. standard of care in this setting is typically 6-9 months. $DRTS is printing numbers that are hard to ignore. 11.2 months in the metastatic cohort after one prior chemo line. pancreatic cancer kills most patients within a year of diagnosis, so the historical bar here is brutally low and these results clear it by a wide margin. three tumor types now: pancreatic, glioblastoma (two complete responses reported may 11), cSCC with FDA pre-market approval module already submitted. the data pattern across indications is consistent. u.s. IMPACT trial enrollment completing next. wiseek.ai/ticker/drts/news/2…

A lot of new investors that don't quite know the $DRTS story selling it off on ASCO data. These data are from disparate, diversely-enrolled trials, with many patients not receiving full tumor coverage. And still Alpha DaRTs is delivering 11 months mOS vs. 6 months SoC... The 17-month mOS from last chemo initiation is an interesting data point but difficult to interpret. The bottom line is that even at these levels Alpha DaRT is a major improvement in SoC that can be COMBINED with $RVMD's daraxonrasib because of its stellar safety. AND that the data from the US-based 40-patient pancreatic trial due around YE will likely look even better.

Just hit!!! 17 months! $DRTS delivers!